Role evidence
Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 7
Treatment-assignment count: 0
Stratification count: 0
Trial Selection Rising
RET fusion
breast cancer · Immune Checkpoint Inhibitor
RET fusion is flagged as trial selection rising because public trials show inclusion required evidence in 9 contexts. FDA CDx context should be reviewed manually.
Threshold snippets
Fragmentation view
Threshold count: 2
Common snippets: MSI-H | MSI-H
Threshold label: Moderate
FDA CDx context
Mapping summary
CDx label: Fda Cdx Context Not Found
CDx maturity score: 1/5
Confidence: Medium
Patent-density signal
Diagnostic appendix
Signal count: 0
Recent signals: 0
Density label: Low
Source links
Evidence paths
https://clinicaltrials.gov/study/NCT07287917 | https://clinicaltrials.gov/study/NCT04190056 | https://clinicaltrials.gov/study/NCT01848834 | https://clinicaltrials.gov/study/NCT07054242 | https://clinicaltrials.gov/study/NCT03222856 | https://clinicaltrials.gov/study/NCT07486687 | https://clinicaltrials.gov/study/NCT04234113 | https://clinicaltrials.gov/study/NCT04787042 | https://clinicaltrials.gov/study/NCT03492918